Dr Reddy’s Lab Announces Commercial Launch Of Anti-COVID Drug 2DG


New Delhi: Dr Reddy’s Laboratories announced the commercial launch of anti-COVID drug 2DG.

“Ideally, 2DG should be prescribed as early as possible by doctors for moderate to severe Covid patients for a maximum duration of up to 10 days,” it said.

The DRDO further said that uncontrolled diabetes, severe cardiac problem, ARDS, severe hepatic and renal impairment patients have not been studied yet with 2DG, and hence caution should be exercised.

“The 2DG should not be given to pregnant and lactating women and patients below 18 years,” it added.

The first batch of DRDO’s anti-Covid-19 drug was released on May 17 by Union Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan.

2-DG can be administered orally by dissolving in water. It works by getting itself lodged in the virus-infected cells. 2-DG stops viral synthesis and energy production thus stopping the growth of the coronavirus .

2-DG is unique in its approach as it selectively accumulates only in the cells infected by the virus.

Comments are closed.